<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01386333</url>
  </required_header>
  <id_info>
    <org_study_id>R-11-232</org_study_id>
    <secondary_id>17783</secondary_id>
    <nct_id>NCT01386333</nct_id>
  </id_info>
  <brief_title>Safety Study of Intranasal Oxytocin in Frontotemporal Dementia</brief_title>
  <acronym>FTDOXY10EF</acronym>
  <official_title>A Phase I Dose Finding Study of Intranasal Oxytocin in Frontotemporal Dementia, Protocol # FTDOXY10EF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Consortium of Canadian Centres for Clinical Cognitive Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxytocin is a hormone produced by the brain that appears to have important roles in social
      cognition and emotion in humans. In a pilot study, the effects of a single dose of oxytocin
      on measures of emotion recognition and behaviour in patients with Frontotemporal Dementia
      were investigated. The results from the pilot study suggested that oxytocin may be associated
      with a modest improvement in neuropsychiatric behaviours seen in patients with Frontotemporal
      Dementia. To further examine the safety and tolerability of oxytocin in this disorder, the
      present study will examine the safety and tolerability of three different doses of intranasal
      oxytocin administered to patients with Frontotemporal Dementia twice daily for 1 week.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>2 week</time_frame>
    <description>Safety and Tolerability of 24 international units (IU), 48 IU and 72 IU of intranasal oxytocin administered twice daily for 1 week to patients with Frontotemporal Dementia as assessed by the number of participants with adverse events. Adverse events will be assessed by a standardized questionnaire and serum sodium levels will be monitored.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory</measure>
    <time_frame>1 week</time_frame>
    <description>Behavioural ratings at baseline and 1 week of oxytocin treatment compared to 1 week of placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frontal Behavioural Inventory</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinicians Global Impression of Change</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating- Frontotemporal Lobar Degeneration</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interpersonal Reactivity Index</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multi-faceted Empathy Test</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Frontotemporal Dementia</condition>
  <arm_group>
    <arm_group_label>Oxytocin 24IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin 24 IU administered intranasally twice daily for 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin 48 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>48 IU of intranasal oxytocin administered twice daily for 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>72 IU oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>72 IU of intranasal oxytocin administered twice daily for 1 week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin</intervention_name>
    <description>Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week</description>
    <arm_group_label>Oxytocin 24IU</arm_group_label>
    <arm_group_label>Oxytocin 48 IU</arm_group_label>
    <arm_group_label>72 IU oxytocin</arm_group_label>
    <arm_group_label>Saline nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Nasal Mist</intervention_name>
    <description>Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts</description>
    <arm_group_label>Saline nasal spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 30-80 years

          -  Meets &quot;Neary criteria&quot; for diagnosis of probable frontotemporal dementia

          -  Neuroimaging (CT, MRI or SPECT scan) supports diagnosis of frontotemporal dementia

          -  Provides written informed consent and has a caregiver or legally acceptable
             representative who provides written informed consent.

        Exclusion Criteria:

          -  Has a history of a myocardial infarction within the last two years or congestive heart
             failure.

          -  Current uncontrolled hypertension

          -  Current bradycardia (rate &lt; 50 beats per minute/bpm) or tachycardia (rate &gt; 100 bpm)

          -  Current hyponatremia

          -  Current use of prostaglandin medications

          -  Females who are pregnant or breastfeeding

          -  Use of any investigational or experimental drug or device within the last 60 days
             prior to screening or within 5 half-lives of the experimental drug , whichever is
             longer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth C Finger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Western Ontario, Lawson Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cognitive Neurology and Alzheimer Research Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2011</study_first_posted>
  <last_update_submitted>November 1, 2013</last_update_submitted>
  <last_update_submitted_qc>November 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Elizabeth Finger</investigator_full_name>
    <investigator_title>Cognitive Neurologist</investigator_title>
  </responsible_party>
  <keyword>Frontotemporal Dementia</keyword>
  <keyword>oxytocin</keyword>
  <keyword>Pick's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

